ELEVIDYS
STN: 125781
Proper Name: delandistrogene moxeparvovec-rokl
Tradename: ELEVIDYS
Manufacturer: Sarepta Therapeutics, Inc.
Indication:
- For the Treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
Product Information
- Package Insert - ELEVIDYS
- Demographic Subgroup Information – delandistrogene moxeparvovec-rokl (ELEVIDYS)
Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.
Supporting Documents
- June 22, 2023 Approval Letter - ELEVIDYS
- June 21, 2023 Summary Basis for Regulatory Action - ELEVIDYS
- Center Director Decisional Memo - ELEVIDYS
- Approval History, Letters, Reviews, and Related Documents - ELEVIDYS